CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

May 2, 2024

Study Completion Date

July 24, 2025

Conditions
Parkinson Disease
Interventions
DRUG

Rivastigmine Transdermal System

Rivastigmine Trandermal Patches applied once a day for up to 12 months

OTHER

Placebo Transdermal System

Placebo Trandermal Patches applied once a day for up to 12 months

Trial Locations (38)

BS8 1NU

Barking, Havering and Redbridge University Hospitals NHS trust, Romford

M13 9WL

Manchester University NHS Foundation Trust, Manchester

LL57 2PW

Betsi Cadwaladr University Health Board, Bangor

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

EH1 3EG

Lothian Health Board NHS, Edinburgh

FK5 4WR

NHS Forth Valley, Larbert

BA1 3NG

Royal United Hospitals Bath NHS Foundation Trust, Bath

AB15 6RE

NHS Grampian, Aberdeen

S75 2EP

Barnsley Hospital NHS Foundation Trust, Barnsley

BH23 2JX

University Hospitals Dorset NHS Foundation Trust, Bournemouth

CF31 1RQ

Princess of Wales Hospital (Cwm Taf Morgannwg University Health Board), Bridgend

BS1 3NU

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol

BS10 5NB

North Bristol NHS Trust, Bristol

BL9 7TD

Pennine Acute Hospitals NHS Trust, Bury

DE22 3NE

University Hospitals of Derby and Burton NHS Foundation Trust, Derby

DD2 1UB

NHS Tayside, Dundee

NE9 6SX

Gateshead Health NHS Foundation Trust, Gateshead

GL1 3NN

Gloucestershire Hospitals NHS Foundation Trust, Gloucester

LS2 3AX

Leeds Teaching Hospitals NHS Trust, Leeds

LE1 5WW

University Hospitals of Leicester NHS Foundation Trust, Leicester

L9 7LJ

The Walton Centre NHS Foundation Trust, Liverpool

W6 8RF

Imperial College Healthcare NHS Trust, London

WC1N 3BG

University College London Hospitals NHS Foundation Trust, London

TS4 3BS

South Tees Hospitals NHS Foundation Trust, Middlesbrough

NE27 0QJ

Northumbria Healthcare NHS Foundation Trust, Newcastle

NE7 7DN

Newcastle Hospitals NHS Foundation Trust, Newcastle

NP18 3XQ

Aneurin Bevan University Health Board, Newport

OX3 9DU

Oxford University Hospitals, Oxford

PE3 9GZ

North West Anglia NHS Foundation Trust, Peterborough

PL6 5FP

University Hospitals Plymouth NHS Trust, Plymouth

PR2 9HT

Lancashire Teaching Hospitals NHS Foundation Trust, Preston

RG1 5AN

Royal Berkshire NHS Foundation Trust, Reading

MA6 8HD

Salford Royal NHS Foundation Trust, Salford

TS19 8PE

North Tees and Hartlepool Hospitals NHS Foundation Trust, Stockton-on-Tees

TA1 5DA

Somerset NHS Foundation Trust, Taunton

WN1 2NN

Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan

LL13 7YP

Betsi Cadwaladr University Health Board, Wrexham

Unknown

Yeovil District Hospital, Yeovil

All Listed Sponsors
collaborator

Royal United Hospitals Bath NHS Foundation Trust

OTHER

lead

University of Bristol

OTHER

NCT04226248 - CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) | Biotech Hunter | Biotech Hunter